GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Gepotidacin tablets (Blujepa, adult renal comments)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Blujepa

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
BLUJEPA: moderate impairment is not always sufficient for eligibility

The newer label includes gonorrhea-specific combined exposure risks not covered by a simple uUTI renal cutoff. No adjustment within a renal band does not override indication-specific QTc avoidance conditions.

Before applying: Confirm indication, weight, interacting medicines and hepatic function; do not invent a reduced gonorrhea regimen to bypass an avoidance condition.

Also check: BLUJEPA: moderate impairment is not always sufficient for eligibility

Official source

BLUJEPA tablets: February 2026 renal and QTc restrictions

Product / population
BLUJEPA uUTI and uncomplicated urogenital gonorrhea; selected indication-specific renal and interaction restrictions.
Renal measure
eGFR (mL/min as printed), body weight and Child-Pugh classification.

The RX mirror and official label are not independent corroborating clinical studies.

Renal dosing, restrictions and evidence limits

The February 2026 label needs no dose adjustment at eGFR 30-89 but avoids use below 30, including dialysis. For gonorrhea, avoid moderate CYP3A4 inhibitors and avoid the combination of two or more exposure factors: weight 45-60 kg, eGFR 30-59, or Child-Pugh B. Strong CYP3A4 inhibitors and severe hepatic impairment are additional avoidance settings. The higher exposure/QTc risk is not addressed by inventing a reduced course. This supplement prevents an older uUTI-focused local summary from being generalized to gonorrhea.

Source revision: February 2026 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80b57cfe-7819-4d95-a57d-014af42f118d

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Gepotidacin tablets (Blujepa, adult renal comments) - selected U.S. label sections

Adult BLUJEPA oral tablets. Uncomplicated urinary infection and gonorrhea regimens are not interchangeable.

Renal method: eGFR; selected section expresses thresholds in mL/min
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

BLUJEPA tablets: February 2026 renal and QTc restrictions

Interaction-dependent renal restriction. Review the complete coadministered regimen; a single-product renal statement does not clear combination risk.

BLUJEPA uUTI and uncomplicated urogenital gonorrhea; selected indication-specific renal and interaction restrictions.

Renal method: eGFR (mL/min as printed), body weight and Child-Pugh classification.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Gepotidacin (Blujepa)

Interaction-dependent renal restriction. Review the complete coadministered regimen; a single-product renal statement does not clear combination risk.

BLUJEPA oral uUTI and uncomplicated urogenital gonorrhea instructions; indication-specific exposure precautions.

Renal method: eGFR (mL/min as printed); do not silently add or remove body-surface-area indexing.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

label version and indication

BLUJEPA: moderate impairment is not always sufficient for eligibility

The newer label includes gonorrhea-specific combined exposure risks not covered by a simple uUTI renal cutoff. No adjustment within a renal band does not override indication-specific QTc avoidance conditions.

How to use this: Confirm indication, weight, interacting medicines and hepatic function; do not invent a reduced gonorrhea regimen to bypass an avoidance condition.

Gepotidacin tablets (Blujepa, adult renal comments) - selected U.S. label sectionsBLUJEPA tablets: February 2026 renal and QTc restrictions

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

Gepotidacin tablets (Blujepa, adult renal comments) - selected U.S. label sections

Adult BLUJEPA oral tablets. Uncomplicated urinary infection and gonorrhea regimens are not interchangeable.

Method: eGFR; selected section expresses thresholds in mL/min

Renal impairment commentsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGepotidacin tablets (Blujepa, adult renal comments) - selected U.S. label sectionsBLUJEPA tablets: February 2026 renal and QTc restrictionsGlobalRPh RX List - Gepotidacin (Blujepa)
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80b57cfe-7819-4d95-a57d-014af42f118d

Product and population scope

Adult BLUJEPA oral tablets. Uncomplicated urinary infection and gonorrhea regimens are not interchangeable.

RDM32-gepotidacin-blujepa-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Gepotidacin tablets (Blujepa, adult renal comments) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult BLUJEPA oral tablets. Uncomplicated urinary infection and gonorrhea regimens are not interchangeable.

Renal method: eGFR; selected section expresses thresholds in mL/min
Source date: 2/2026
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal impairment comments

No renal adjustment is required at eGFR 60-89 or 30-59 mL/min. Avoid use below 30 mL/min, including dialysis, because increased exposure can increase QT-prolongation risk.

RDM32-gepotidacin-blujepa-1 · Source locator: 8.6

Indication-dependent caution

For the gonorrhea indication, avoid use in moderate renal impairment when other factors that increase gepotidacin exposure are present. This renal comment does not supply an indication-specific antibiotic course.

RDM32-gepotidacin-blujepa-2 · Source locator: 8.6; 5.1

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80b57cfe-7819-4d95-a57d-014af42f118d
Retrieved
2026-09-05
DailyMed Set ID
80b57cfe-7819-4d95-a57d-014af42f118d
Label revision
2/2026
Renal-function method
eGFR; selected section expresses thresholds in mL/min
Source date/version
2/2026
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
bfb7549f49a79ca522eaa3a02d88b296a0c1e67143ebbaf86028c61653ed7c65
Official

BLUJEPA tablets: February 2026 renal and QTc restrictions

Open original reference

Open / share this exact local source

DailyMed / GlaxoSmithKline · BLUJEPA uUTI and uncomplicated urogenital gonorrhea; selected indication-specific renal and interaction restrictions.

Renal method: eGFR (mL/min as printed), body weight and Child-Pugh classification.
Source date: February 2026
Retrieved: 2026-09-07

Interaction-dependent renal restriction. Review the complete coadministered regimen; a single-product renal statement does not clear combination risk.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The February 2026 label needs no dose adjustment at eGFR 30-89 but avoids use below 30, including dialysis. For gonorrhea, avoid moderate CYP3A4 inhibitors and avoid the combination of two or more exposure factors: weight 45-60 kg, eGFR 30-59, or Child-Pugh B. Strong CYP3A4 inhibitors and severe hepatic impairment are additional avoidance settings. The higher exposure/QTc risk is not addressed by inventing a reduced course. This supplement prevents an older uUTI-focused local summary from being generalized to gonorrhea.

RDM39-official-gepotidacin-blujepa-bfa7cad890-C1 · Source locator: Sections 5.1, 7.1 and 8.6; highlights revision

Source-specific limits

The RX mirror and official label are not independent corroborating clinical studies.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80b57cfe-7819-4d95-a57d-014af42f118d
Retrieved
2026-09-07
Exact label title
BLUJEPA tablets: February 2026 renal and QTc restrictions
DailyMed Set ID
80b57cfe-7819-4d95-a57d-014af42f118d
Labeler
GlaxoSmithKline LLC
Label revision
February 2026
SPL version
3
FDA application
NDA218230
Renal-function method
eGFR (mL/min as printed), body weight and Child-Pugh classification.
Source date/version
February 2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
db963f2a48cb92e65ef7a062ec7a10aafdb00ab28d81226a3992279ae23fd5f8
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Gepotidacin (Blujepa)

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · BLUJEPA oral uUTI and uncomplicated urogenital gonorrhea instructions; indication-specific exposure precautions.

Renal method: eGFR (mL/min as printed); do not silently add or remove body-surface-area indexing.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Interaction-dependent renal restriction. Review the complete coadministered regimen; a single-product renal statement does not clear combination risk.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No dose adjustment is required at eGFR 30-89, but avoid BLUJEPA below 30, including dialysis, because increased exposure can prolong QTc. For uncomplicated urogenital gonorrhea, additional restrictions apply: avoid with moderate CYP3A4 inhibitors or when two or more exposure factors coexist (weight 45-60 kg, eGFR 30-59, Child-Pugh B). Thus, the isolated phrase no adjustment at moderate impairment does not establish eligibility for that indication. Strong CYP3A4 inhibitors and other label QTc precautions also remain relevant.

RDM39-rxlist-gepotidacin-blujepa-65f0df2efe-C1 · Source locator: Selected renal dosing, use in renal impairment, warnings and clinical pharmacology subsections; see named sections in summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/blujepa-drug/
Retrieved
2026-09-07
Renal-function method
eGFR (mL/min as printed); do not silently add or remove body-surface-area indexing.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
10c2c6dd9b088ea26c90e5b89908aab1673add6c7ce53c0fafd636773ff96b72

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80b57cfe-7819-4d95-a57d-014af42f118d
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
5a264dc677ae556accdee3308f50ba732a569187916c933ba75765ed51dc5cf6
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report